BeyondSpring (BYSI)
Develops Plinabulin for cancer indications with standard-of-care agents.
Something off on this page? Send us feedback.
Develops Plinabulin with standard-of-care agents for multiple cancer indications, while retaining an equity interest in SEED Therapeutics. The clinical-stage company has no approved candidates for sale and remains substantially dependent on Plinabulin's development, approval, and eventual commercialization.
Develops Plinabulin, its lead cancer-treatment candidate, with standard-of-care agents across multiple cancer indications. The program has completed two Phase 3 development programs and has continued Phase 3 progress in non-small cell lung cancer.
An equity interest in SEED Therapeutics provides a separate related-pipeline thread; SEED's activities should not be merged with Plinabulin's. Operations span New Jersey, Beijing, and Dalian, while no candidate is approved for sale in China, the United States, the European Union, or elsewhere.
The business is substantially dependent on the development, approval, and eventual commercialization of Plinabulin and any other candidates.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.5M · Total debt $171.0K · Total assets $14.6M · Shareholders' equity −$35.6M
- Revenue
- $0
- Operating income
- −$1.7M
- Net income
- −$849.0K
No dividends on record.
| Institutions21 holders · as of Mar 31, 2026 | 14.55% | 5.98M shares | |
| Insiders4 holders · as of Jul 6, 2026 | 0.19% | 78.1K shares | |
| Strategic holders2 holders · as of Oct 20, 2025 | 6.74% | 2.77M shares | |
| Otherremainder | 78.52% | 32.28M shares |
41.12M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Decheng Capital LLCInstitution | 9.24% | 3.80M | 13Fas of Mar 31, 2026 |
Decheng Capital China Life Sciences USD Fund III, L.P.Strategic10 percent owner | 3.69% | 1.52M | Form 4filed Oct 20, 2025 ↗ |
Shenzhen Sangel Capital Management Limited CompanyStrategic | 3.05% | 1.25M | 13G/Afiled Feb 14, 2022 ↗ |
BlackRock, Inc.Institution | 1.58% | 649,462 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 1.48% | 607,934 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Oct 17, 2025 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10 percent owner | −45,513 | $1.76 |
| Oct 16, 2025 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10 percent owner | −85,798 | $1.72 |
| Oct 15, 2025 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10 percent owner | −17,960 | $1.65 |
| Oct 14, 2025 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10 percent owner | −28,495 | $1.65 |
| Oct 13, 2025 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10 percent owner | −107,361 | $1.70 |
- Amgen
Reference pegfilgrastim therapy for CIN prevention
- Pfizer
Pegfilgrastim biosimilar for CIN prevention
- Amneal Pharmaceuticals
Pegfilgrastim biosimilar for CIN prevention
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BeyondSpring | $0.6209 | +3.04% | $25.1M | — | — | — | — |
| Amgen | $445.00 | +0.49% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Pfizer | $28.99 | −0.15% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Amneal Pharmaceuticals | $18.01 | −0.33% | $5.77B | 37.0 | 18.1 | 1.8 | +9.9% |
| Median | 37.0 | 18.1 | 2.6 | +9.7% |